TYAN Showcases HPC, AI and Storage Server Platforms Featuring 2nd Gen Intel® Xeon® Scalable Processors at SC19
19.11.2019 17:00:00 EET | Business Wire | Press release
TYAN®, an industry-leading server platform design manufacturer and a subsidiary of MiTAC Computing Technology Corporation, exhibits a broad selection of HPC, AI, storage and cloud server platforms that are optimized for enterprise and data center markets at SC19 through November 21st, Booth # 1601 in Denver’s Colorado Convention Center.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191119005008/en/
TYAN HPC Server Platforms Boost Performance with 2nd Gen Intel Xeon Scalable Processors for Enterprises and Data Centers (Photo: Business Wire)
“Data is the foundation of the new economy, and how organizations effectively move, store and process will help determine their level of success,” said Danny Hsu, Vice President of MiTAC Computing Technology Corporation's TYAN Business Unit. “By leveraging the 2nd gen Intel® Xeon® Scalable processors, TYAN’s leading portfolio of HPC, storage and cloud server platforms enable to help our customers accelerate innovation, drive business value, and bring products and services to market faster.”
TYAN HPC and Storage Server Platforms Boost Performance with 2nd Gen Intel Xeon Scalable Processors
TYAN’s HPC server platforms are built on the 2nd gen Intel Xeon Scalable processors with the addition of Intel® Deep Learning Boost technology and Intel® Optane™ DC persistent memory that enable to deliver higher performance for a range of HPC and AI applications. The new Thunder HX FT83-B7119 features high CPU-to-GPU bandwidth for various parallel workloads. The 4U system supports 10 double-width PCIe x16 slots for GPU deployment, a single-wide x16 networking card, up to 3TB of system RAM, and its front-loading 24 hot-swap, tool-less 3.5” drive bays enable easy access with simple, tool-free installation.
More HPC platforms on display include, Thunder HX FT77D-B7109 in a 4U two-socket design with integrated Intel® Omni-Path100 gigabit networking fabric for massively parallel workloads such as scientific computing and large-scale facial recognition; Thunder HX FT48T-B7105 in a 4U pedestal workstation design delivering maximum I/O to professional power users for 3D rendering and image processing; Thunder HX GA88-B5631 with high density and performance in a 1U single-socket chassis supporting 12 DIMM slots and 5 PCIe x16 slots for machine learning and artificial intelligence applications.
Powered by 2nd gen Intel Xeon Scalable processors, TYAN storage platforms offer a variety of tiered storage implementation scenarios for data centers and enterprises across a range of Thunder SX FA100-B7118, a 4U 100-bay high-capacity cold storage, Thunder SX TN76-B7102, a 2U server storage with 24 DDR4 DIMM slots and twelve 3.5” hot-swap drive bays for data virtualization and in-memory databases, and the Thunder SX GT62H-B7106, a 1U high-performance all-flash storage with 10 U.2 NVMe drive bays for extremely high speed data streaming applications.
The new Thunder SX GT90-B7113 is a 1U dual-socket high-density storage platform supporting twelve 3.5” hot-swap SATA drives (SAS drives are supported by configuration). mounted to a service drawer and four 2.5” hot-swap NVMe U.2 drive bays in a 35” chassis depth. The platform is designed for CSP server-based software-defined storage applications by allowing serviceability and density within the same server.
TYAN also showcases entry server platforms highlighting Intel® Xeon® E-2200 processors to offer professional-grade performance. The Thunder CX GT24E-B5556 is a 1U server optimized for cost-effective cloud gaming applications with support for up to 4 DDR4 DIMM slots, 1 double-width GPU card, and dual 10GBase-T Ethernet ports; the Thunder CX GX38-B5550 is a 1U compact sever with sub-400mm deep chassis and support for two 3.5" internal SATA drive bays for edge computing.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191119005008/en/
Contact information
MiTAC Computing Technology Corporation/ TYAN Business Unit
Fenny Chen
fenny.chen@tyan.com.tw
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom